Jonathan Miller
Stock Analyst at Evercore ISI
(3.07)
# 2,679
Out of 4,693 analysts
57
Total ratings
59.6%
Success rate
4.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMVP PMV Pharmaceuticals | Maintained: Buy | $4 | $1.29 | +210.08% | 3 | Sep 1, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $76 | $56.82 | +33.76% | 3 | Aug 31, 2026 | |
| ARVN Arvinas | Rated: Buy | $19 → $14 | $9.28 | +50.86% | 4 | Aug 10, 2026 | |
| NTLA Intellia Therapeutics | Upgraded: Buy | $16 → $24 | $12.69 | +89.20% | 6 | Aug 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintained: Buy | $23 | $14.35 | +60.28% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Maintained: Buy | $15 | $3.07 | +388.60% | 3 | May 27, 2026 | |
| NKTX Nkarta | Maintained: Buy | $9 | $2.70 | +233.33% | 1 | May 18, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $23 → $22 | $18.89 | +16.46% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Maintained: Buy | $25 | $7.07 | +253.61% | 2 | May 5, 2026 | |
| ERAS Erasca | Maintained: Buy | $11 → $24 | $16.76 | +43.20% | 2 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $15 | $7.43 | +101.88% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $29.67 | +61.78% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 → $13 | $1.55 | +738.71% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $29.71 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.56 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $5.49 | +9.29% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $13.51 | -11.18% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $6.87 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.04 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.85 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.02 | n/a | 2 | May 5, 2021 |
PMV Pharmaceuticals
Sep 1, 2026
Maintained: Buy
Price Target: $4
Current: $1.29
Upside: +210.08%
CRISPR Therapeutics AG
Aug 31, 2026
Maintained: Buy
Price Target: $76
Current: $56.82
Upside: +33.76%
Arvinas
Aug 10, 2026
Rated: Buy
Price Target: $19 → $14
Current: $9.28
Upside: +50.86%
Intellia Therapeutics
Aug 7, 2026
Upgraded: Buy
Price Target: $16 → $24
Current: $12.69
Upside: +89.20%
4D Molecular Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $23
Current: $14.35
Upside: +60.28%
Editas Medicine
May 27, 2026
Maintained: Buy
Price Target: $15
Current: $3.07
Upside: +388.60%
Nkarta
May 18, 2026
Maintained: Buy
Price Target: $9
Current: $2.70
Upside: +233.33%
Janux Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $23 → $22
Current: $18.89
Upside: +16.46%
Entrada Therapeutics
May 5, 2026
Maintained: Buy
Price Target: $25
Current: $7.07
Upside: +253.61%
Erasca
Apr 28, 2026
Maintained: Buy
Price Target: $11 → $24
Current: $16.76
Upside: +43.20%
Apr 13, 2026
Maintained: Buy
Price Target: $13 → $15
Current: $7.43
Upside: +101.88%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $29.67
Upside: +61.78%
Mar 9, 2026
Maintained: Buy
Price Target: $1 → $13
Current: $1.55
Upside: +738.71%
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $29.71
Upside: -
Jan 26, 2026
Maintained: Buy
Price Target: n/a
Current: $3.56
Upside: -
Nov 28, 2025
Maintained: Buy
Price Target: $6
Current: $5.49
Upside: +9.29%
Sep 30, 2025
Maintained: Buy
Price Target: $12
Current: $13.51
Upside: -11.18%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $6.87
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: n/a
Current: $4.04
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.85
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $9.02
Upside: n/a